This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Brown, J. E. Articles by Coleman, R. E. Search for Related Content PubMed PubMed Citation Articles by Brown, J. E. Articles by Coleman, R. E.

Effect of Chemotherapy on Skeletal Health in Male Survivors from Testicular Cancer and Lymphoma

Authors' Affiliations: ¹ Academic Unit of Clinical Oncology, Weston Park Hospital; ² Trent Cancer Registry; and ³ Metabolic Bone Unit, University of Sheffield, Sheffield, United Kingdom

Requests for reprints: Janet E. Brown, Cancer Research UK Clinical Centre-Leeds, JIF Building, St. James's University Hospital, Beckett Street, Leeds LS9 7TF, United Kingdom. Phone: 44-113-2064184; Fax: 44-113-2460136; E-mail: J.E.Brown{at}leeds.ac.uk.

Purpose: There are concerns over the late effects of cancer therapy, including accelerated bone loss leading to increased risk of osteoporosis. Treatment-related bone loss is well recognized in breast and prostate cancer, due to overt hypogonadism, but there has been little evaluation of the skeletal effects of chemotherapy alone in adults. This study assesses the extent of bone loss due to previous chemotherapy in men.

Experimental Design: The bone mineral density (BMD) of men who had received previously chemotherapy with curative intent for lymphoma or testicular cancers was compared with that of an age-matched population of men from a cancer control population that had not received chemotherapy. BMD was measured by dual-energy X-ray scanning. Additionally, measurement of sex hormones and the bone turnover markers N-telopeptide fragment of type I collagen and bone-specific alkaline phosphatase were done. All statistical tests were two sided.

Results: One hundred fifteen chemotherapy-treated patients and 102 cancer controls were recruited. There was no statistical difference in BMD between the chemotherapy and control groups at either spine or hip and the mean BMD values in both groups were no lower than that of a reference population. There were no significant differences in estradiol, luteinizing hormone, and testosterone, but follicle-stimulating hormone values were significantly higher in the chemotherapy group (P = 0.011). The mean values of NH₂-terminal telopeptide fragment of type I collagen and bone-specific alkaline phosphatase were within the reference ranges.

Conclusions: The absence of accelerated bone loss following chemotherapy is reassuring and suggests that standard dose cytotoxic chemotherapy has no lasting clinically important direct effects on bone metabolism.